| Code | CSB-RA005273MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to GT-103, targeting complement factor H (CFH), a critical regulatory protein in the complement alternative pathway. CFH functions as a key inhibitor of complement activation by binding C3b and serving as a cofactor for factor I-mediated C3b cleavage, thereby preventing excessive complement-mediated inflammation and tissue damage. Dysregulation of CFH is implicated in numerous complement-associated disorders, including age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), dense deposit disease, and C3 glomerulopathy. Genetic variants and autoantibodies against CFH have been strongly associated with increased disease susceptibility and severity in these conditions.
The reference antibody GT-103 has been utilized in complement research to investigate CFH expression, localization, and functional activity in various pathological contexts. This biosimilar provides researchers with a reliable tool for studying complement regulation mechanisms, examining CFH-related disease pathogenesis, and exploring potential therapeutic interventions targeting the complement system. It supports investigations into inflammatory disorders, renal diseases, and retinal pathologies where complement dysregulation plays a central role.
There are currently no reviews for this product.